acute coronary syndrome
Conditions
Interventions
Group 1:receive medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
Group 2:receive medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)+once a month, subcutaneous injection of 1 injection of PCSK9 inhibitor each time
Group 3:receive medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)+twice a month, subcutaneous injection of 1 injection of PCSK9 inhibitor each time
Sponsors
The First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-85 years, gender unlimited; 2. Diagnosed with acute coronary syndrome; 3. The fasting LDL-C>=1.8mmol/L (70mg/dL); 4. Subjects participated in the study voluntarily and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled hypertension (systolic blood pressure > 180mmHg or diastolic blood pressure > 110mmHg); 2. After treatment, patients with heart failure still have New York grade III-IV or LVEF 3 times the normal value); 6. Lipoprotein or plasma apheresis was performed within one year prior to the start of observation; 7. Patients who are breastfeeding or pregnant; 8. Combined with severe non-cardiovascular disease and life expectancy < 3 years; 9. Patients who are allergic to PCSK9 inhibitors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total cholesterol;Triglyceride;High density lipoprotein;Low density lipoprotein;Lipoprotein a; | — |
Countries
China
Contacts
Public ContactWang Liansheng
Outcome results
None listed